Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

被引:449
作者
Leen, Ann M.
Myers, G. Doug
Sili, Uluhan
Huls, M. Helen
Weiss, Heidi
Leung, Kathryn S.
Carrum, George
Krance, Robert A.
Chang, Chung-Che
Molldrem, Jeffrey J.
Gee, Adrian P.
Brenner, Malcolm K.
Heslop, Helen E.
Rooney, Cliona M.
Bollard, Catherine M. [1 ]
机构
[1] Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
[2] Baylor Coll Med, Methodist Hosp, Dept Pediat, Houston, TX 77030 USA
[3] Baylor Coll Med, Methodist Hosp, Dept Immunol, Houston, TX 77030 USA
[4] Baylor Coll Med, Methodist Hosp, Dept Med, Houston, TX 77030 USA
[5] Baylor Coll Med, Methodist Hosp, Dept Virol, Houston, TX 77030 USA
[6] Texas Childrens Hosp, Houston, TX 77030 USA
[7] Cornell Univ, TMHRI, Methodist Hosp, Dept Pathol,Weill Med Coll, Houston, TX 77030 USA
[8] Univ Texas, MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA
关键词
D O I
10.1038/nm1475
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunocompromised individuals are at high risk for life-threatening diseases, especially those caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus. Conventional therapeutics are primarily active only against CMV, and resistance is frequent. Adoptive transfer of polyclonal cytotoxic T lymphocytes (CTLs) specific for CMV or EBV seems promising, but it is unclear whether this strategy can be extended to adenovirus, which comprises many serotypes. In addition, the preparation of a specific CTL line for each virus in every eligible individual would be impractical. Here we describe genetic modification of antigen-presenting cell lines to facilitate the production of CD4(+) and CD8(+) T lymphocytes specific for CMV, EBV and several serotypes of adenovirus from a single cell culture. When administered to immunocompromised individuals, the single T lymphocyte line expands into multiple discrete virus-specific populations that supply clinically measurable antiviral activity. Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host.
引用
收藏
页码:1160 / 1166
页数:7
相关论文
共 32 条
[11]   Extensive cross-reactivity of CD4+ adenovirus-specific T cells:: Implications for immunotherapy and gene therapy [J].
Heemskerk, B ;
Veltrop-Duits, LA ;
van Vreeswijk, T ;
ten Dam, MM ;
Heidt, S ;
Toes, REM ;
van Tol, MJD ;
Schilham, MW .
JOURNAL OF VIROLOGY, 2003, 77 (11) :6562-6566
[12]   Rapid and quantitative detection of human adenovirus DNA by real-time PCR [J].
Heim, A ;
Ebnet, C ;
Harste, G ;
Pring-Åkerblom, P .
JOURNAL OF MEDICAL VIROLOGY, 2003, 70 (02) :228-239
[13]  
HESLOP HE, 1994, NEW ENGL J MED, V331, P679
[14]   Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes [J].
Heslop, HE ;
Ng, CYC ;
Li, CF ;
Smith, CA ;
Loftin, SK ;
Krance, RA ;
Brenner, MK ;
Rooney, CM .
NATURE MEDICINE, 1996, 2 (05) :551-555
[15]   Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases [J].
Khanna, R ;
Burrows, SR .
ANNUAL REVIEW OF MICROBIOLOGY, 2000, 54 :19-48
[16]   Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells [J].
Leen, AM ;
Sili, U ;
Vanin, EF ;
Jewell, AM ;
Xie, WD ;
Vignali, D ;
Piedra, PA ;
Brenner, MK ;
Rooney, CM .
BLOOD, 2004, 104 (08) :2432-2440
[17]   Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications [J].
Leen, AM ;
Sili, U ;
Savoldo, B ;
Jewell, AM ;
Piedra, PA ;
Brenner, MK ;
Rooney, CM .
BLOOD, 2004, 103 (03) :1011-1019
[18]   Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease [J].
Lion, T ;
Baumgartinger, R ;
Watzinger, F ;
Matthes-Martin, S ;
Suda, M ;
Preuner, S ;
Futterknecht, B ;
Lawitschka, A ;
Peters, C ;
Pötschger, U ;
Gadner, H .
BLOOD, 2003, 102 (03) :1114-1120
[19]   Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) [J].
Myers, GD ;
Krance, RA ;
Weiss, H ;
Kuehnle, I ;
Demmler, G ;
Heslop, HE ;
Bollard, CM .
BONE MARROW TRANSPLANTATION, 2005, 36 (11) :1001-1008
[20]   INFUSIONS OF DONOR LEUKOCYTES TO TREAT EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
PAPADOPOULOS, EB ;
LADANYI, M ;
EMANUEL, D ;
MACKINNON, S ;
BOULAD, F ;
CARABASI, MH ;
CASTROMALASPINA, H ;
CHILDS, BH ;
GILLIO, AP ;
SMALL, TN ;
YOUNG, JW ;
KERNAN, NA ;
OREILLY, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (17) :1185-1191